1. Introduction {#sec1}
===============

Diffuse gliomas are the most common primary brain tumors in adults and encompass a heterogeneous group of tumors with different histopathological features, aggressiveness, imaging, response to treatment and survival.

They are primarily defined by the histopathological tumor tissue analysis and subdivided by the World Health Organization (WHO) classification into grade II (low grade glioma), grade III (anaplastic glioma) and grade IV (glioblastoma multiforme, GBM).

Accurate distinction between different grades is of significant clinical importance because of its strong prognostic and treatment decision-making implications ([@bb0023]). However, histopathological criteria of the grading system present some limitations such as the lack of reproducibility and the prognostic heterogeneity within the same group ([@bb0027]). To improve this classification, some molecular markers not only have diagnostic and prognostic implications, but also therapeutic efficacy prediction (1p/19q co-deletion, IDH1/IDH2 mutations and MGMT promoter methylation) ([@bb0028]). However, these approaches require a resection or a biopsy and have limitations induced by intra-tumoral heterogeneity ([@bb0035]). Furthermore, there is a need to identify criteria of aggressiveness for inoperable patients.

MRI is a part of the daily management of the patients by providing anatomical and vascular information. The presence or the absence of T1 enhancement after gadolinium-chelate injection, necrosis, mass effect and surrounding tumor edema are established parameters used in characterizing tumor aggressiveness ([@bb006])*.* The presence of contrast enhancement in diffuse glioma, related to the permeability of the blood--brain-barrier (BBB) reflecting neovascularization, is often regarded as a sign of malignancy. However, it presents some limitations and does not allow for reliable separation between different grades. For example, although the absence of contrast enhancement is a commonly used criterion for identifying grade II gliomas, it does not eliminate formally a malignant tumor ([@bb0010]; [@bb0031]). In contrast, the presence of contrast enhancement and even necrosis, characteristic of GBM, can be observed in pure grade III oligodendrogliomas.

In this context, multimodal imaging based on MRI and PET parameters, by assessing tumor pathophysiology such as microvasculature, metabolism, proliferation or cellularity, could be of additional value.

Previous reports have described and compared the performance of glioma grading using advanced MRI techniques such as relative cerebral blood volume (rCBV), apparent diffusion coefficient (ADC), and metabolites of Magnetic Resonance Spectroscopy (MRS) ([@bb002]; [@bb0014]; [@bb0021]; [@bb0035]; [@bb0038]; [@bb0039]; [@bb0040]). Others focus specifically on glioma grading with the thymidine analog \[^18^F\]-fluoro-[l]{.smallcaps}-thymidine (\[^18^F\]-FLT), developed as a positron emission tomography (PET) tracer to assess the proliferation activity of tumors in vivo, particularly in brain tumors ([@bb003]; [@bb004]; [@bb0011]; [@bb0018]). Even if these multimodal imaging parameters are useful to distinguish grade II from higher grades (anaplastic and GBM), the differentiating criteria of grade III from grade IV gliomas, two groups with different prognoses and management, are still poorly defined.

The aim of this study was to compare the performance of these advanced MR techniques, namely perfusion, diffusion and proton MR spectroscopy (^1^H-MRS) with that of \[^18^F\]-FLT-PET, by pre-operatively assessing the diagnostic accuracy of each parameter in differentiating glioma grades.

2. Methods {#sec2}
==========

2.1. Patients {#sec2.1}
-------------

This study was based on a prospective clinical trial funded by INCa (Institut National du Cancer) and approved by the local ethics committee and AFSSAPS agreement (ClinicalTrials.gov identifier: [NCT00850278](http://www.ncbi.nlm.nih.gov/nuccore/nct00850278){#interref1}). Forty patients were included in the Caen University Hospital. Inclusion criteria were: a presumed diffuse glioma amenable to surgical resection or biopsy, age greater than or equal to 18, KPS greater than or equal to 50, normal blood cell count, normal biological hepatic functions and a signed informed consent. The group sizes of the different tumor grades were the result of the incidence of each tumor in this prospective study. Patients first underwent \[^18^F\]-FLT-PET, followed by multiparametric MRI/MRS within the same week and prior to surgery. Single voxel MRS was localized in the area with maximum visible uptake of \[^18^F\]-FLT. Thereafter, patients underwent surgery, resection or biopsy depending on the location of the tumor, and the specimens were histopathologically evaluated by an experienced neuropathologist (ELZ). Majority of patients had image-guided total or subtotal surgical resection ([Table 1](#t0005){ref-type="table"}). For patients with biopsy only, the biopsy was guided by the area with maximum visible uptake of \[^18^F\]-FLT. For grade III tumors or for difficult cases, the diagnosis and grading were reviewed by the national multicentric network "Prise en charge des OLigodendrogliomes Anaplasiques POLA" ([@bb0016]).

2.2. Image acquisition {#sec2.2}
----------------------

*MR imaging* was performed on a 1.5 Tesla GEMS version HDXt 15.0. After scout-view and coronal T2-weighted imaging, an axial FLAIR (Fluid Attenuated Inversion Recovery) sequence was performed (24 slices, slice spacing 5.5, pixel resolution 0.47 × 0.47 mm, TR/TE = 9602/150 ms). Diffusion Weighted Imaging (DWI) was performed using Spin-Echo-Echo Planar Imaging (SE-EPI) (3 diffusion directions, 36 slices, slice spacing: 7 mm, pixel resolution: 1.09 × 1.09 mm, TR/TE = 6000/96 ms, b ≈ 0 and b ≈ 1000 s•mm^2^). For perfusion, dynamic T2\*-weighted EPI images were acquired 30 s before, during the first pass of Gd-DOTA (Dotarem®, Guerbet, France) and 1 min after with a standard 0.1 mmol/kg body weight dose (14 slices**,** 35 repetitions, slice spacing: 7 mm, pixel resolution 2.19 × 2.19 mm, TR/TE = 2280/60 ms). Immediately thereafter, a 3DT1-weighted sequence, 3DT1w-Gd (124 slices, slice spacing 1.5, pixel resolution 1.01 × 1.01 mm, TR/TE = 17/3 ms) was performed to evaluate the tumor contrast enhancement. Finally, MRS data were acquired in a single voxel (1 cm^3^) localized in the tumor in the area of maximal uptake of FLT and in the normal-appearing contralateral side with PRESS MRS sequence with multiple TE (35, 144, 288 ms) and water suppression.

*FLT-PET* \[^18^F\]-FLT was produced by the LDM-TEP group and synthesized at the CYCERON TEP center as previously described by [@bb0018]. Acquisitions were performed on a General Electric Discovery VCT 64 PET scanner. Images of the brain were acquired 40 min after the intravenous injection of 5 MBq/kg of ^18^F-FLT and lasted 10 min, to match a clinically feasible approach. The attenuation-corrected images were reconstructed with an OSEM 2D algorithm (9 subsets and 2 iterations) and filtered in 3D with a Butterworth filter.

2.3. Image analysis {#sec2.3}
-------------------

*ADC maps* were computed from DWI. The ADC (apparent diffusion coefficient) maps were calculated pixel-by-pixel using ImageJ software ([[http://rsb.info.nih.gov/ij/]{.ul}](http://rsb.info.nih.gov/ij/){#interref2}, 1997--2012) using the following equation: ADC = −\[ln(S/S~0~)\]/b where S is the signal (averaged over the 3 directions) acquired, b = 1000, and S~0~ = the signal acquired without diffusion gradient. Values were expressed as 10^−6^ mm^2^/s. r*CBV maps* were computed using perfusion imaging. Variations of the T2\* signal in the tissue, which is proportional to the concentration of the contrast agent, were calculated with in-house macros based on ImageJ software as: ΔR^2\*^(t) = −ln(S(t)/S~0~), where S~0~ = the signal intensity before contrast agent injection, and S(t) = the signal intensity over time. Then, CBV maps were generated by integrating the area under the γ-variate fitted curves to avoid an effect of recirculation. Images were then normalized by dividing CBV maps with the mean value of the normal-appearing contralateral side. *Coregistration:* ADC maps, rCBV maps, FLAIR and PET-FLT images were coregistered with trilinear interpolation, rigid matching and normalized mutual information on 3DT1w-Gd images (PMOD 3.1® software).

2.4. ROI segmentation {#sec2.4}
---------------------

The hypersignal in FLAIR images was manually delineated to define a Region Of Interest (ROI) in order to use a homogeneous method to define a pathological area (tumor, peripheral edema and infiltration areas) for the different grades, despite the presence or absence of T1 enhancement. When present, necrosis was excluded.

2.5. Parameter extraction {#sec2.5}
-------------------------

Tumor ROIs were reported for each modality (rCBV, ADC, T1 enhancement, FLT-PET) to extract the mean value for each modality, the maximum value for rCBV, CE and PET-FLT, and the minimum value for ADC. To avoid sensitivity to extreme values, the minimum value was associated with the 10th percentile (p10) and the maximum value with the 90th percentile (p90). In MRS, choline (Cho), creatine (Cr), N-Acethyl-Aspartate (NAA), phospholipids and lactate were quantified with SA/GE software (GE) to obtain peak amplitudes and areas (proportional to concentration and relaxation) from spectra with water resonance suppression, and expressed as a ratio.

2.6. Statistical analysis {#sec2.6}
-------------------------

Statistical analyses were performed with JMP© software. Analysis was performed between all grades. *p*-Values of comparisons between grades were calculated using the non-parametric Wilcoxon test. A *p*-value \< 0.05 was considered statistically significant. Ordinal logistic regression was used to assess the degree of correlation (R^2^) of each parameter with the grade. Only R^2^ values with *p*-value \< 0.05 were considered significant.

3. Results {#sec3}
==========

3.1. Patients and tumor characteristics {#sec3.1}
---------------------------------------

Among the 40 patients included in the study, 1 had an incomplete MRI examination. Of the 39 remaining patients, all presented histopathologically proven diffuse glioma based on WHO criteria and were eligible in the final analysis (ranging from 21 to 79 years old, 17 women and 22 men). The diagnosis was established from biopsy specimens (*n* = 9) or from resection (10 patients with a partial resection and 20 patients with a macroscopically complete resection) yielding 7 patients with grade II glioma, 9 patients with grade III glioma and 23 patients with grade IV glioma. [Table 1](#t0005){ref-type="table"} shows patients and tumor characteristics.

3.2. Interest of multimodal imaging at the individual level {#sec3.2}
-----------------------------------------------------------

[Fig. 1](#f0005){ref-type="fig"} illustrates the multimodal imaging of tumors of each grade. Grade II gliomas typically looked like a non-enhancing lesion that had no modification on CBV maps and no \[^18^F\]-FLT uptake ([Fig. 1](#f0005){ref-type="fig"}). Most grade III gliomas showed a slightly enhancing lesion with mild \[^18^F\]-FLT uptake ([Fig. 1](#f0005){ref-type="fig"}: Grade III (a)). In contrast, grade IV gliomas typically exhibited a strong contrast enhancement, elevated rCBV, and high \[^18^F\]-FLT uptake ([Fig. 1](#f0005){ref-type="fig"}: Grade IV (a)). Interestingly, some grade III glioma presented a profile indicative of a GBM, i.e. sustained contrast enhancement, strong modification in ADC, elevated Cho/Cr and rCBV, appearance of lipids/lactate but \[^18^F\]-FLT clearly demonstrated a weak tumor cell proliferation ([Fig. 1](#f0005){ref-type="fig"}: Grade III (b)).

On the opposite, a grade IV glioma presented non-objectivable modification in perfusion but an intense \[^18^F\]-FLT uptake favoring the diagnosis of a GBM instead of a grade III glioma ([Fig. 1](#f0005){ref-type="fig"}: Grade IV (b)).

3.3. Comparisons of imaging parameters between grades {#sec3.3}
-----------------------------------------------------

Between grade II and grade IV gliomas rCBV~mean,~ rCBV~max,~ FLT~mean,~ FLT~max,~ CE~mean~, CE~max,~ Cho/Cr and Cho/NAA showed significant differences ([Table 2](#t0010){ref-type="table"}). The most relevant parameter was FLT~max~ (*p* \< 0.001) ([Fig. 2](#f0010){ref-type="fig"}, [Table 2](#t0010){ref-type="table"}).

Between grade III and grade IV gliomas, ADC~mean~, ADC~min~, rCBV~mean,~ rCBV~max,~ FLT~mean,~ FLT~max,~ CE~mean~, and CE~max~ showed significant differences ([Table 2](#t0010){ref-type="table"}). The most relevant parameter was FLT~max~ (*p* \< 0.0001) ([Fig. 2](#f0010){ref-type="fig"}, [Table 2](#t0010){ref-type="table"}). Cho/Cr showed significant differences between grade II and grade III gliomas (*p* = 0.03).

The parameter showing the best significant correlation with the grade was FLT~max~ (R^2^ = 0.5, *p* \< 0.0001) ([Table 2](#t0010){ref-type="table"}).

4. Discussion {#sec4}
=============

The prognosis and management of patients with diffuse glioma are strongly dependent on the accurate grading of the tumor. MRI plays a crucial role in the assessment of aggressiveness of gliomas before surgery but may remain insufficient to forecast prognosis of diffuse gliomas. Therefore, multimodal imaging parameters with advanced MRI (CBV and ADC), MRS and \[^18^F\]-FLT-PET could identify relevant markers to better predict the grading of gliomas.

Among advanced technics, Cho/Cr ratio presented interesting performances for the discrimination of different grades. This was also shown in our study, particularly between grade II and grade III gliomas (*p* = 0.03). Indeed, Cho/Cr is well known to be correlated with tumor cell proliferation ([@bb0013]) and usually presents significant differences between low grade and high grade gliomas ([@bb0021]; [@bb0032]; [@bb0038]; [@bb0040]). Our results suggest that the use of Cho/Cr ratio could be of interest in the management of grade II and grade III rather than \[^18^F\]-FLT PET, that did not show significant differences between these grades. rCBV has been shown to be correlated with tumor aggressiveness and with grade in enhancing and in non-enhancing lesions ([@bb001]; [@bb0022]; [@bb0024]; [@bb0029]; [@bb0033]; [@bb0034]). rCBV has a better diagnostic performance in differentiating between low grade and high grade gliomas than Cho/Cr and Cho/NAA ratios obtained with MRS ([@bb0021]), ADC ([@bb002]) or Ktrans ([@bb0020]). While most studies compare high grade and low grade, our study suggests that CBV~mean~ and CBV~max~ significantly differ between patients with grade III and patients with grade IV. For Zonari et al., rCBV is the most important parameter for accurate tumor grading by differentiating grade II from III gliomas ([@bb0039]).

Along with \[^18^F\]-FDG, numerous other PET radiotracers have been developed (for review, see ([@bb008]; [@bb0036])) to assess tumor aggressiveness such as 3′-\[^18^F\]fluoro-3′-deoxy-[l]{.smallcaps}-thymidine (\[^18^F\]-FLT) ([@bb0018]) or amino acid metabolism by *o*-(2-\[^18^F\]fluoroethyl)-[l]{.smallcaps}-tyrosine (\[^18^F\]-FET) ([@bb0015]) or methyl-\[^11^C\]-[l]{.smallcaps}-methionine (\[^11^C\]-MET) ([@bb007]). Among these tracers, \[^18^F\]-FLT correlates with cell proliferation, particularly in brain tumors ([@bb003]). This tracer has already been used by us and others to assess grade ([@bb009]), treatment efficacy ([@bb005]; [@bb0030]) or prognosis ([@bb0017]). \[^18^F\]-FLT has also been assessed and compared with other tracers as a marker for high grade gliomas and probably more adapted for the grading compared to \[^11^C\]-MET or \[^18^F\]-FET in this setting ([@bb004]; [@bb0011]; [@bb0018]; [@bb0019]; [@bb0025]). In agreement with these reports, our study showed that \[^18^F\]-FLT parameters were not sensitive enough to distinguish grade II from grade III gliomas, but was the best parameter to distinguish grade IV from lower grade gliomas. Our results are in line of previous work that already showed the interest of using \[^18^F\]-FLT to differentiate low and high grade gliomas ([@bb0037]). We are also aware that PET imaging and more precisely FLT PET are restricted, at the present time, to few hospital or research centers. In the present study, we propose that FLT PET adds information in presence of suspicious patients where MRI may be not sensitive enough before any treatment is decided but where biopsy examination may lose some very aggressive "hot spot" thanks to the great spatial heterogeneity.

Of note, we chose a static and delayed acquisition of \[^18^F\]-FLT images since a dynamic acquisition (e.g. 2 h of acquisition) may not be realistic for routine clinical practice. It has been shown that \[^18^F\]-FLT uptake occurs due to increased transport through the blood--brain barrier (BBB) and proliferation. When we focused on the condition for which the \[^18^F\]-FLT tracer seemed to be relevant, i.e. the distinction between patients with grade III with CE and those with grade IV, all the tumors had an alteration of the BBB.

Although the advanced MRI and PET parameters show more and more interest and could become more accessible in the assessment of glioma ([@bb0012]; [@bb0026]), studies have often evaluated independently the interest of using either MRI or PET. In the present study, we benefit from the ability to compare the parameters from both advanced MRI and PET for each patient and illustrate their complementary role in glioma grading.

5. Conclusion {#sec5}
=============

In conclusion, this study shows that \[^18^F\]-FLT could be of interest in glioma classification particularly in differentiating grade IV glioblastoma from grade III or grade II gliomas. FLT~max~ seems to be the best parameter to achieve this goal. Our work also illustrates the added value to acquire both, advanced MRI and \[^18^F\]-FLT PET, to overcome the limitations of conventional imaging for doubtful patients.
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![Multimodal aspect on imaging of a patient with a grade II glioma, two patients with a grade III glioma and two patients with a grade IV glioma.](gr1){#f0005}

![Graphic representation of the parameters used to distinguish between grade II gliomas (*n* = 7), grade III gliomas (*n* = 9) and grade IV gliomas (*n* = 23).](gr2){#f0010}

###### 

Patients and tumor characteristics (GGII: glioma grade II, GGIII: glioma grade III, GGIV: glioma grade IV, M: male, F: female, R: right, L: left, CC: corpus callosum, CE: contrast enhancement after gadolinium injection, nec: necrosis, Yes: 1, No: 0, EOR: extent of resection, PE: partial resection, CR: complete resection, B: biopsy, NA: not available).

  Patient   Sex   Age   KPS   Tumor location                         CE   Nec   EOR   WHO grade   Pathological diagnosis
  --------- ----- ----- ----- -------------------------------------- ---- ----- ----- ----------- ------------------------
  1         F     55    100   Frontal, L                             0    0     PR    2           Oligodendroglioma
  2         M     62    NA    Temporal, R                            0    0     CR    2           Oligodendroglioma
  3         F     53    100   Temporal, L                            0    0     CR    2           Oligodendroglioma
  4         F     60    NA    Frontal, R                             0    0     CR    2           Oligodendroglioma
  5         M     38    100   Frontal, L                             0    0     PR    2           Oligodendroglioma
  6         F     44    100   Parietal, temporal, R                  0    0     PR    2           Oligodendroglioma
  7         F     27    100   Central                                0    0     PR    2           Oligodendroglioma
  8         F     60    90    CC                                     1    0     CR    3           Oligodendroglioma
  9         F     41    90    Frontal, R                             1    0     CR    3           Oligodendroglioma
  10        F     29    100   Parietal, L                            0    0     CR    3           Oligoastrocytoma
  11        F     25    100   Frontal, L                             0    0     CR    3           Oligoastrocytoma
  12        F     48    NA    Frontal, L                             0    0     CR    3           Oligodendroglioma
  13        M     47    80    Temporal, insular, R                   1    0     B     3           Oligodendroglioma
  14        F     46    90    Frontal, L                             0    0     CR    3           Oligodendroglioma
  15        M     50    90    frontal, temporal, insular, L          1    1     PR    3           Astrocytoma
  16        F     38    100   Temporal, R                            1    1     CR    3           Oligodendroglioma
  17        M     58    80    Parietal, occipital, R                 1    1     PR    4           Glioblastoma
  18        F     74    80    Parietal, temporal, occipital, L       1    1     CR    4           Glioblastoma
  19        M     73    80    Frontal, parietal, temporal, R         1    1     CR    4           Glioblastoma
  20        M     59    80    Frontal, R                             1    0     CR    4           Glioblastoma
  21        M     70    100   Parietal, central, L                   1    1     CR    4           Glioblastoma
  22        F     44    70    Frontal, bilateral, multifocal         1    1     B     4           Glioblastoma
  23        F     46    80    Frontal, CC, L                         1    1     PR    4           Glioblastoma
  24        M     52    80    Parietal, L                            1    1     CR    4           Glioblastoma
  25        F     70    80    Frontal, occipital, multifocal         1    1     B     4           Glioblastoma
  26        M     24    100   Frontal, temporal                      1    1     CR    4           Glioblastoma
  27        M     52    80    Frontal, R                             1    1     CR    4           Glioblastoma
  28        F     64    80    Frontal, parietal, CC, multifocal, L   1    1     B     4           Glioblastoma
  29        M     28    100   Parietal, temporal, insular, L         1    1     PR    4           Glioblastoma
  30        M     58    90    temporal, R                            1    1     CR    4           Glioblastoma
  31        M     79    80    Frontal, bilateral                     1    1     B     4           Glioblastoma
  32        M     67    80    Occipital                              1    1     B     4           Glioblastoma
  33        M     53    70    Frontal, multifocal                    1    1     B     4           Glioblastoma
  34        M     64    80    Frontal, L                             1    1     CR    4           Glioblastoma
  35        M     52    80    Frontal, R                             1    1     PR    4           Glioblastoma
  36        M     74    80    Frontal, parietal, L                   1    1     CR    4           Glioblastoma
  37        M     72    60    Frontal, CC, bilateral, multifocal     1    1     B     4           Glioblastoma
  38        M     62    80    Occipital, CC, L                       1    1     PR    4           Glioblastoma
  39        M     67    90    Temporal, insular, R                   1    1     B     4           Glioblastoma

###### 

Quantification of imaging parameters for grade II gliomas (*n* = 7), grade III gliomas (*n* = 9) and grade IV (*n* = 23). *p*-Values from the Wilcoxon test, values of R^2^ with significant *p*-value from a logistic regression analysis between the grade and the parameters (NS: not significant).

                               Grade II (mean ± SD)   Grade III (mean ± SD)   Grade IV (mean ± SD)   Wilcoxon test (*p*-value)   Logistic regression                    
  ---------------------------- ---------------------- ----------------------- ---------------------- --------------------------- --------------------- --------- ------ ----------
  ADC~mean~ (10^−6^ mm^2^/s)   1201 ± 89              1345 ± 130              1176 ± 129             NS                          0.013                 NS        0.04   NS
  ADC~min~ (10^−6^ mm^2^/s)    903 ± 66               962 ± 55                837 ± 71               NS                          \<0.001               NS        0.15   \<0.01
  rCBV~mean~                   1.18 ± 0.19            1.11 ± 0.35             1.59 ± 0.43            NS                          0.010                 0.035     0.15   \<0.01
  rCBV~max~                    1.88 ± 0.37            1.77 ± 0.52             2.73 ± 0.68            NS                          \<0.01                0.013     0.21   \<0.001
  Cho/Cr                       1.41 ± 0.20            3.71 ± 4.04             3.65 ± 1.97            0.03                        NS                    \<0.01    0.03   NS
  NAA/Cr                       1.15 ± 0.28            0.85 ± 0.40             0.89 ± 0.33            NS                          NS                    NS        0.01   NS
  Cho/NAA                      1.18 ± 0.41            4.91 ± 4.66             3.84 ± 2.44            NS                          NS                    0.021     0.01   NS
  FLT~mean~ (g/ml)             0.27 ± 0.09            0.25 ± 0.09             0.61 ± 0.23            NS                          \<0.001               \<0.01    0.36   \<0.0001
  FLT~max~ (g/ml)              0.34 ± 0.09            0.33 ± 0.14             1.27 ± 0.56            NS                          \<0.0001              \<0.001   0.5    \<0.0001
